{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:15:19Z","timestamp":1793970919273,"version":"4.8.0"},"reference-count":43,"publisher":"American Veterinary Medical Association (AVMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"s001\">\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To assess the effect of oral cannabidiol (CBD) administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with idiopathic epilepsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"s002\">\n                    <jats:title>DESIGN<\/jats:title>\n                    <jats:p>Randomized blinded controlled clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"s003\">\n                    <jats:title>ANIMALS<\/jats:title>\n                    <jats:p>26 client-owned dogs with intractable idiopathic epilepsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"s004\">\n                    <jats:title>PROCEDURES<\/jats:title>\n                    <jats:p>Dogs were randomly assigned to a CBD (n = 12) or placebo (14) group. The CBD group received CBD-infused oil (2.5 mg\/kg [1.1 mg\/lb], PO) twice daily for 12 weeks in addition to existing antiepileptic treatments, and the placebo group received noninfused oil under the same conditions. Seizure activity, adverse effects, and plasma CBD concentrations were compared between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"s005\">\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>2 dogs in the CBD group developed ataxia and were withdrawn from the study. After other exclusions, 9 dogs in the CBD group and 7 in the placebo group were included in the analysis. Dogs in the CBD group had a significant (median change, 33%) reduction in seizure frequency, compared with the placebo group. However, the proportion of dogs considered responders to treatment (\u2265 50% decrease in seizure activity) was similar between groups. Plasma CBD concentrations were correlated with reduction in seizure frequency. Dogs in the CBD group had a significant increase in serum alkaline phosphatase activity. No adverse behavioral effects were reported by owners.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"s006\">\n                    <jats:title>CONCLUSIONS AND CLINICAL RELEVANCE<\/jats:title>\n                    <jats:p>Although a significant reduction in seizure frequency was achieved for dogs in the CBD group, the proportion of responders was similar between groups. Given the correlation between plasma CBD concentration and seizure frequency, additional research is warranted to determine whether a higher dosage of CBD would be effective in reducing seizure activity by \u2265 50%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2460\/javma.254.11.1301","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T15:17:09Z","timestamp":1557328629000},"page":"1301-1308","source":"Crossref","is-referenced-by-count":144,"title":["Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy"],"prefix":"10.2460","volume":"254","author":[{"given":"Stephanie","family":"McGrath","sequence":"first","affiliation":[{"name":"1Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa R.","family":"Bartner","sequence":"additional","affiliation":[{"name":"1Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Rao","sequence":"additional","affiliation":[{"name":"1Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Packer","sequence":"additional","affiliation":[{"name":"1Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Gustafson","sequence":"additional","affiliation":[{"name":"1Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"J Small Anim Pract","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1748-5827.2012.01251.x","article-title":"Canine idiopathic epilepsy: prevalence, risk factors and outcome associated with cluster seizures and status epilepticus","volume":"53","author":"Monteiro","year":"2012"},{"key":"ref2","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/jvim.13841","article-title":"2015 ACVIM small animal consensus statement on seizure management in dogs","volume":"30","author":"Podell","year":"2016"},{"key":"ref3","series-title":"Vet J","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.tvjl.2007.03.002","article-title":"The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs","volume":"176","author":"Volk","year":"2008"},{"key":"ref4","series-title":"J Clin Psychiatry","first-page":"439","article-title":"Complex partial seizure symptoms affected by marijuana abuse","volume":"51","author":"Ellison","year":"1990"},{"key":"ref5","series-title":"Epilepsia","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/epi.12610","article-title":"The case for medical marijuana in epilepsy","volume":"55","author":"Maa","year":"2014"},{"key":"ref6","series-title":"Rev Neurol Dis","first-page":"103","article-title":"Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature","volume":"4","author":"Mortati","year":"2007"},{"key":"ref7","series-title":"Epilepsy Behav","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.yebeh.2015.02.043","article-title":"Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy","volume":"45","author":"Press","year":"2015"},{"key":"ref8","series-title":"J Pharmacol Exp Ther","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1124\/jpet.109.159145","article-title":"Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo","volume":"332","author":"Jones","year":"2010"},{"key":"ref9","series-title":"J Psychiatr Res","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jpsychires.2012.08.012","article-title":"Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors","volume":"46","author":"Campos","year":"2012"},{"key":"ref10","series-title":"Proc Natl Acad Sci U S A","doi-asserted-by":"publisher","first-page":"7895","DOI":"10.1073\/pnas.0511232103","article-title":"Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression","volume":"103","author":"Carrier","year":"2006"},{"key":"ref11","series-title":"Br J Pharmacol","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011"},{"key":"ref12","series-title":"Proc Natl Acad Sci U S A","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1073\/pnas.1211204110","article-title":"Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses","volume":"110","author":"Sylantyev","year":"2013"},{"key":"ref13","series-title":"J Pharmacol Exp Ther","first-page":"26","article-title":"Cannabidiol\u2014antiepileptic drug comparisons and interactions in experimentally induced seizures in rats","volume":"201","author":"Consroe","year":"1977"},{"key":"ref14","series-title":"Eur J Pharmacol","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0014-2999(82)90264-3","article-title":"Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice","volume":"83","author":"Consroe","year":"1982"},{"key":"ref15","series-title":"Seizure","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.seizure.2012.03.001","article-title":"Cannabidiol exerts anticonvulsant effects in animal models of temporal lobe and partial seizures","volume":"21","author":"Jones","year":"2012"},{"key":"ref16","series-title":"FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy","year":"2019"},{"key":"ref17","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018"},{"key":"ref18","series-title":"Can J Vet Res","first-page":"178","article-title":"Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs","volume":"82","author":"Bartner","year":"2018"},{"key":"ref19","series-title":"BMC Vet Res","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12917-015-0462-1","article-title":"International veterinary epilepsy task force consensus proposal: diagnostic approach to epilepsy in dogs","volume":"11","author":"De Risio","year":"2015"},{"key":"ref20","series-title":"J Vet Pharmacol Ther","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1365-2885.1985.tb00934.x","article-title":"Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison","volume":"8","author":"Schwartz-Porsche","year":"1985"},{"key":"ref21","series-title":"J Am Vet Med Assoc","first-page":"1091","article-title":"Therapeutic serum concentrations of primidone and its metabolites, phenobarbital and phenylethylmalonamide in epileptic dogs","volume":"182","author":"Cunningham","year":"1983"},{"key":"ref22","series-title":"J Am Vet Med Assoc","first-page":"1449","article-title":"Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992\u20131996)","volume":"213","author":"Trepanier","year":"1998"},{"key":"ref23","series-title":"Fed Reg","first-page":"53395","article-title":"Statement of principles on industrial hemp","volume":"81","year":"2016"},{"key":"ref24","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2460\/javma.2003.223.1293","article-title":"Development and validation of a questionnaire for measuring behavior and temperament traits in pet dogs","volume":"223","author":"Hsu","year":"2003"},{"key":"ref25","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2460\/javma.2005.227.1755","article-title":"Evaluation of a behavioral assessment questionnaire for use in the characterization of behavioral problems of dogs relinquished to animal shelters","volume":"227","author":"Segurson","year":"2005"},{"key":"ref26","series-title":"Appl Anim Behav Sci","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0168-1591(00)00210-0","article-title":"Development and validation of a novel method for evaluating behavior and temperament in guide dogs","volume":"72","author":"Serpell","year":"2001"},{"key":"ref27","series-title":"BMC Vet Res","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12917-017-1000-0","article-title":"Investigating the potential of the anti-epileptic drug imepitoin as a treatment for co-morbid anxiety in dogs with idiopathic epilepsy","volume":"13","author":"Packer","year":"2017"},{"key":"ref28","series-title":"Vet J","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.tvjl.2012.05.018","article-title":"Questionnaire-based behaviour analysis of Cavalier King Charles Spaniels with neuropathic pain due to Chiari-like malformation and syringomyelia","volume":"194","author":"Rutherford","year":"2012"},{"key":"ref29","series-title":"Epilepsy Behav","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.yebeh.2011.03.018","article-title":"Behavioral changes in dogs associated with the development of idiopathic epilepsy","volume":"21","author":"Shihab","year":"2011"},{"key":"ref30","series-title":"Lancet Neurol","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016"},{"key":"ref31","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017"},{"key":"ref32","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018"},{"key":"ref33","series-title":"Epilepsy Behav","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","article-title":"Open-label use of highly purified CBD (Epidiolex) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes","volume":"86","author":"Devinsky","year":"2018"},{"key":"ref34","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018"},{"key":"ref35","series-title":"Pharmacology","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000137430","article-title":"Chronic administration of cannabidiol to healthy volunteers and epileptic patients","volume":"21","author":"Cunha","year":"1980"},{"key":"ref36","series-title":"J Basic Clin Pharm","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016"},{"key":"ref37","series-title":"Epilepsia","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017"},{"issue":"suppl 1","key":"ref38","series-title":"Seizure","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.seizure.2004.04.020","article-title":"Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies","volume":"13","author":"Miura","year":"2004"},{"key":"ref39","series-title":"Biochem Pharmacol","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1016\/0006-2952(89)90432-2","article-title":"Effect of cannabidiol on cytochrome P-450 isozymes","volume":"38","author":"Bornheim","year":"1989"},{"key":"ref40","series-title":"Biochem Pharmacol","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0006-2952(91)90017-Y","article-title":"Influence of chronic oral intake of cannabis extract on oxidative and hydrolytic metabolism of xenobiotics in rat","volume":"41","author":"Khanna","year":"1991"},{"key":"ref41","series-title":"Curr Drug Metab","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2174\/1389200217666151210142051","article-title":"Cannabinoids and cytochrome P450 interactions","volume":"17","author":"Zendulka","year":"2016"},{"key":"ref42","series-title":"Psychopharmacologia","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF00421539","article-title":"Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin","volume":"37","author":"Chesher","year":"1974"},{"key":"ref43","series-title":"Epilepsia","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/254\/11\/javma.254.11.1301.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/254\/11\/javma.254.11.1301.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/254\/11\/javma.254.11.1301.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T20:36:31Z","timestamp":1696538191000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/254\/11\/javma.254.11.1301.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":43,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.2460\/javma.254.11.1301","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}